Cargando…

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

BACKGROUND: This review describes the research and development process of gantenerumab, a fully human anti-amyloid monoclonal antibody in development to treat early symptomatic and asymptomatic Alzheimer’s disease (AD). Anti-amyloid monoclonal antibodies can substantially reverse amyloid plaque path...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bateman, Randall J., Cummings, Jeffrey, Schobel, Scott, Salloway, Stephen, Vellas, Bruno, Boada, Mercè, Black, Sandra E., Blennow, Kaj, Fontoura, Paulo, Klein, Gregory, Assunção, Sheila Seleri, Smith, Janice, Doody, Rachelle S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707418/ https://www.ncbi.nlm.nih.gov/pubmed/36447240 http://dx.doi.org/10.1186/s13195-022-01110-8

Ejemplares similares

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
por: Ostrowitzki, Susanne, et al.
Publicado: (2017)

Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
por: Ostrowitzki, Susanne, et al.
Publicado: (2018)

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
por: Klein, Gregory, et al.
Publicado: (2019)

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease
por: Novakovic, Dijana, et al.
Publicado: (2013)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease [Corrigendum]
Publicado: (2014)

Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
por: Joseph‐Mathurin, Nelly, et al.
Publicado: (2022)

Trends in Healthcare Resource Use Preceding Diagnosis of Alzheimer's Disease Dementia
por: Abbass, Ibrahim M., et al.
Publicado: (2023)

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
por: Assunção, Sheila Seleri, et al.
Publicado: (2022)

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
por: Tolar, Martin, et al.
Publicado: (2020)

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
por: Söderberg, Linda, et al.
Publicado: (2022)

Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2022)

Disease Modeling and Model‐Based Meta‐Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer’s Disease
por: Retout, Sylvie, et al.
Publicado: (2022)

In silico exploration of amyloid‐related imaging abnormalities in the gantenerumab open‐label extension trials using a semi‐mechanistic model
por: Aldea, Roxana, et al.
Publicado: (2022)

Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force
por: Aisen, P. S., et al.
Publicado: (2021)

Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
por: Cummings, Jeffrey
Publicado: (2023)

Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)
por: Nave, Stephane, et al.
Publicado: (2017)

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2021)

A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
por: Blennow, Kaj
Publicado: (2017)

Plasma tau levels in Alzheimer's disease
por: Zetterberg, Henrik, et al.
Publicado: (2013)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
por: Sabbagh, Marwan, et al.
Publicado: (2013)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Their Role in Clinical Chemistry
por: Blennow, Kaj, et al.
Publicado: (2000)

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease
por: Doody, Rachelle S, et al.
Publicado: (2015)

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
por: Bateman, Randall J, et al.
Publicado: (2011)

Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
por: Sabbagh, Marwan N., et al.
Publicado: (2019)

The Amyloid-β Pathway in Alzheimer’s Disease
por: Hampel, Harald, et al.
Publicado: (2021)

Modeling the course of Alzheimer's disease to improve clinical trials: symposium report
por: Spiegel, René, et al.
Publicado: (2013)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Assessment of Plasma Amyloid-β(42/40) and Cognitive Decline Among Community-Dwelling Older Adults
por: Giudici, Kelly Virecoulon, et al.
Publicado: (2020)

Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity
por: Ferris, Steven, et al.
Publicado: (2013)

Predicting progression of Alzheimer's disease
por: Doody, Rachelle S, et al.
Publicado: (2010)

CSF tau and β-amyloid as biomarkers for mild cognitive impairment
por: Hampel, Harald, et al.
Publicado: (2004)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010)

Correction: Predicting progression of Alzheimer's disease
por: Doody, Rachelle S, et al.
Publicado: (2010)

Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach
por: Morató, Xavier, et al.
Publicado: (2022)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Aducanumab: Appropriate use recommendations
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7cten6ru9095kvrj053sl0a5rb